Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck ProQuad by Quarter
ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M) ($M)
Merck ProQuad: $235M in Q2 2026, down 13.9% from a year earlier.
Latest, Q2 2026
235
Period ended Jun 30, 2026
Change on a year earlier
-13.9%
273 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Where the Q2 2026 figure comes from
“|| ProQuad | 235 | 273 | (14) | % | (15) | % | 434 | 395 | 10 | % | 8 | %”
Source: Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up proQuad
Cite this data
StockData. (2026). Merck ProQuad ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-proquad
See every metric in the Merck KPI table. Data updated Oct 26, 2026.